A phase 3 study shows tafasitamab combined with lenalidomide and R-CHOP significantly improves outcomes for untreated DLBCL patients.

ProBioGen and Spica Therapeutics partner to advance ST101, a first-in-class anti-CD163 antibody targeting immunosuppressive tumor macrophages.

BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancer FDA Fast Track Designation reflects the potential of BGB-B2033 in an area of high unmet need ...

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, ...

Data showed encouraging results in patients with higher CLDN18.2 expression regardless of PD-L1 expression level, with a median PFS of 16.6 months, ORR of 68% and median DoR of 18 months PRINCETON, ...

In therapeutic antibody development the fragment crystallizable (Fc) region is far more than just an antigen-binding aid; it's role is much larger, functioning as the antibody’s functional control ...

Mothers with intrauterine transmission of human cytomegalovirus (CMV) to their newborns despite preconception immunity had higher levels of neutralizing antibodies but had weaker antibody-dependent ...

Sanofi's SAR446523 gains FDA orphan drug status, offering hope for relapsed multiple myeloma patients with its targeted monoclonal antibody approach. Sanofi's investigational GPRC5D monoclonal ...

The engineering and functional characterization of the Fc domain are key to therapeutic antibodies’ efficacy, safety, and pharmacokinetics. The Fc domain is responsible for mediating interactions with ...